Literature DB >> 27044763

KASL clinical practice guidelines: management of hepatitis C.

.   

Abstract

Keywords:  Guidelines; Hepatitis C; KASL; Management

Mesh：

Substances：

Year:  2016        PMID： 27044763      PMCID： PMC4825161          DOI： 10.3350/cmh.2016.22.1.76

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN： 2287-2728


× No keyword cloud information.
  489 in total

Review 1.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 2.  Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review.

Authors:  Victoria A Sublette; Mark W Douglas; Kirsten McCaffery; Jacob George; Kathryn Nicholson Perry
Journal:  Liver Int       Date:  2013-04-14       Impact factor: 5.828

3.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.

Authors:  Jianmeng Chen; Jeffry Florian; Wendy Carter; Russell D Fleischer; Thomas S Hammerstrom; Pravin R Jadhav; Wen Zeng; Jeffrey Murray; Debra Birnkrant
Journal:  Gastroenterology       Date:  2013-03-05       Impact factor: 22.682

4.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Authors:  Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

5.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

6.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

Review 7.  How to optimize current treatment of genotype 2 hepatitis C virus infection.

Authors:  Sebastián Marciano; Adrián C Gadano
Journal:  Liver Int       Date:  2014-02       Impact factor: 5.828

8.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users.

Authors:  Markus Backmund; Kirsten Meyer; Brian R Edlin
Journal:  Clin Infect Dis       Date:  2004-10-26       Impact factor: 9.079

9.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

10.  High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.

Authors:  Fiona McPhee; Yoshiyuki Suzuki; Joji Toyota; Yoshiyasu Karino; Kasuaki Chayama; Yoshiiku Kawakami; Min Lung Yu; Sang Hoon Ahn; Hiroki Ishikawa; Rafia Bhore; Nannan Zhou; Dennis Hernandez; Patricia Mendez; Hiromitsu Kumada
Journal:  Adv Ther       Date:  2015-07-09       Impact factor: 3.845
View more
  36 in total

Review 1.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

2.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

3.  The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.

Authors:  Kyeong Sam Ok; Sook-Hyang Jeong; Eun Sun Jang; Young Seok Kim; Youn Jae Lee; In Hee Kim; Sung Bum Cho; Si Hyun Bae; Han Chu Lee
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

4.  Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.

Authors:  Sajjad Iqbal; Muhammad Haroon Yousuf; Muhammad Iftikhar Yousaf
Journal:  World J Gastroenterol       Date:  2017-11-28       Impact factor: 5.742

5.  Occupational blood exposures in health care workers: incidence, characteristics, and transmission of bloodborne pathogens in South Korea.

Authors:  Ju Hyun Lee; Junhyeon Cho; Yung Jung Kim; Sang Hyuk Im; Eun Sun Jang; Jin-Wook Kim; Hong Bin Kim; Sook-Hyang Jeong
Journal:  BMC Public Health       Date:  2017-10-18       Impact factor: 3.295

6.  Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data.

Authors:  Moran Ki; Hwa Young Choi; Kyung-Ah Kim; Eun Sun Jang; Sook-Hyang Jeong
Journal:  Gut Liver       Date:  2017-11-15       Impact factor: 4.519

Review 7.  Current status of and strategies for hepatitis C control in South Korea.

Authors:  Beom Kyung Kim; Eun Sun Jang; Jeong Han Kim; Soo Young Park; Song Vogue Ahn; Hyung Joon Kim; Do Young Kim
Journal:  Clin Mol Hepatol       Date:  2017-09-19

Review 8.  Current status and strategies for viral hepatitis control in Korea.

Authors:  Dong Hyun Sinn; Eun Ju Cho; Ji Hoon Kim; Do Young Kim; Yoon Jun Kim; Moon Seok Choi
Journal:  Clin Mol Hepatol       Date:  2017-09-19

9.  Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.

Authors:  Hyun Woong Lee; Ki Young Yoo; Joung Won Won; Hyung Joon Kim
Journal:  Gut Liver       Date:  2017-09-15       Impact factor: 4.519

Review 10.  Current status of hepatitis C virus infection and countermeasures in South Korea.

Authors:  Sook-Hyang Jeong; Eun Sun Jang; Hwa Young Choi; Kyung-Ah Kim; Wankyo Chung; Moran Ki
Journal:  Epidemiol Health       Date:  2017-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.